Literature DB >> 34193999

Engineered single-domain antibodies tackle COVID variants.

James E Voss.   

Abstract

Entities:  

Keywords:  Immunology; Medical research; SARS-CoV-2

Year:  2021        PMID: 34193999     DOI: 10.1038/d41586-021-01721-5

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  10 in total

1.  Nanobody approval gives domain antibodies a boost.

Authors:  Chris Morrison
Journal:  Nat Rev Drug Discov       Date:  2019-07       Impact factor: 84.694

2.  Preparing for the Future - Nanobodies for Covid-19?

Authors:  Ram Sasisekharan
Journal:  N Engl J Med       Date:  2021-04-07       Impact factor: 91.245

3.  The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions.

Authors:  Fiona A Harding; Marcia M Stickler; Jennifer Razo; Robert B DuBridge
Journal:  MAbs       Date:  2010-05-01       Impact factor: 5.857

4.  Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses.

Authors:  Sham Nambulli; Yufei Xiang; Natasha L Tilston-Lunel; Linda J Rennick; Zhe Sang; William B Klimstra; Douglas S Reed; Nicholas A Crossland; Yi Shi; W Paul Duprex
Journal:  Sci Adv       Date:  2021-05-26       Impact factor: 14.136

5.  An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.

Authors:  Leo Hanke; Laura Vidakovics Perez; Daniel J Sheward; Hrishikesh Das; Tim Schulte; Ainhoa Moliner-Morro; Martin Corcoran; Adnane Achour; Gunilla B Karlsson Hedestam; B Martin Hällberg; Ben Murrell; Gerald M McInerney
Journal:  Nat Commun       Date:  2020-09-04       Impact factor: 14.919

6.  Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape.

Authors:  Hrishikesh Das; Hejun Liu; Florian N Gohr; Lea-Marie Jenster; Lisa D J Schiffelers; Yonas M Tesfamariam; Miki Uchima; Jennifer D Wuerth; Paul-Albert Koenig; Beate M Kümmerer; Karl Gatterdam; Natalia Ruetalo; Maria H Christensen; Caroline I Fandrey; Sabine Normann; Jan M P Tödtmann; Steffen Pritzl; Leo Hanke; Jannik Boos; Meng Yuan; Xueyong Zhu; Jonathan L Schmid-Burgk; Hiroki Kato; Michael Schindler; Ian A Wilson; Matthias Geyer; Kerstin U Ludwig; B Martin Hällberg; Nicholas C Wu; Florian I Schmidt
Journal:  Science       Date:  2021-01-12       Impact factor: 47.728

7.  Antibody evasion by the P.1 strain of SARS-CoV-2.

Authors:  Wanwisa Dejnirattisai; Daming Zhou; Piyada Supasa; Chang Liu; Alexander J Mentzer; Helen M Ginn; Yuguang Zhao; Helen M E Duyvesteyn; Aekkachai Tuekprakhon; Rungtiwa Nutalai; Beibei Wang; César López-Camacho; Jose Slon-Campos; Thomas S Walter; Donal Skelly; Sue Ann Costa Clemens; Felipe Gomes Naveca; Valdinete Nascimento; Fernanda Nascimento; Cristiano Fernandes da Costa; Paola Cristina Resende; Alex Pauvolid-Correa; Marilda M Siqueira; Christina Dold; Robert Levin; Tao Dong; Andrew J Pollard; Julian C Knight; Derrick Crook; Teresa Lambe; Elizabeth Clutterbuck; Sagida Bibi; Amy Flaxman; Mustapha Bittaye; Sandra Belij-Rammerstorfer; Sarah C Gilbert; Miles W Carroll; Paul Klenerman; Eleanor Barnes; Susanna J Dunachie; Neil G Paterson; Mark A Williams; David R Hall; Ruben J G Hulswit; Thomas A Bowden; Elizabeth E Fry; Juthathip Mongkolsapaya; Jingshan Ren; David I Stuart; Gavin R Screaton
Journal:  Cell       Date:  2021-03-30       Impact factor: 41.582

8.  High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme.

Authors:  Thomas J Esparza; Negin P Martin; George P Anderson; Ellen R Goldman; David L Brody
Journal:  Sci Rep       Date:  2020-12-22       Impact factor: 4.996

9.  Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2.

Authors:  Sham Nambulli; Zhengyun Xiao; Heng Liu; Yufei Xiang; Zhe Sang; W Paul Duprex; Dina Schneidman-Duhovny; Cheng Zhang; Yi Shi
Journal:  Science       Date:  2020-11-05       Impact factor: 47.728

10.  An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike.

Authors:  Michael Schoof; Bryan Faust; Reuben A Saunders; Smriti Sangwan; Veronica Rezelj; Nick Hoppe; Morgane Boone; Christian B Billesbølle; Cristina Puchades; Caleigh M Azumaya; Huong T Kratochvil; Marcell Zimanyi; Ishan Deshpande; Jiahao Liang; Sasha Dickinson; Henry C Nguyen; Cynthia M Chio; Gregory E Merz; Michael C Thompson; Devan Diwanji; Kaitlin Schaefer; Aditya A Anand; Niv Dobzinski; Beth Shoshana Zha; Camille R Simoneau; Kristoffer Leon; Kris M White; Un Seng Chio; Meghna Gupta; Mingliang Jin; Fei Li; Yanxin Liu; Kaihua Zhang; David Bulkley; Ming Sun; Amber M Smith; Alexandrea N Rizo; Frank Moss; Axel F Brilot; Sergei Pourmal; Raphael Trenker; Thomas Pospiech; Sayan Gupta; Benjamin Barsi-Rhyne; Vladislav Belyy; Andrew W Barile-Hill; Silke Nock; Yuwei Liu; Nevan J Krogan; Corie Y Ralston; Danielle L Swaney; Adolfo García-Sastre; Melanie Ott; Marco Vignuzzi; Peter Walter; Aashish Manglik
Journal:  Science       Date:  2020-11-05       Impact factor: 63.714

  10 in total
  1 in total

Review 1.  Single-Domain Antibodies as Therapeutics for Respiratory RNA Virus Infections.

Authors:  Keke Huang; Tianlei Ying; Yanling Wu
Journal:  Viruses       Date:  2022-05-27       Impact factor: 5.818

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.